Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 63
Selected: 0
NCT IDTitle
NCT00112957Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT00003102Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT04729543MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
NCT02643303A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
NCT00140855A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
NCT00006046Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer
NCT00072410Radiolabeled Monoclonal Antibody in Treating Patients With Advanced Ovarian Epithelial Cancer
NCT03164772Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
NCT05736367Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT02659540Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT00679289Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
NCT02963831A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
NCT00291473Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
NCT01975831A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
NCT00623831A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
NCT02336165Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
NCT03017326Paediatric Hepatic International Tumour Trial
NCT02898116Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer
NCT00291486Capecitabine and 131I-huA33 in Patients With Metastatic Colorectal Cancer
NCT01810016NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT00106158Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
NCT00145158Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
NCT02334735A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
NCT00803569Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
NCT00199901Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
NCT00199836A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
NCT00142454NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
NCT01220999A Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer
NCT00112242Immunotherapy of Stage III/IV Melanoma Patients
NCT02425306Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
NCT00084799Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
NCT00520299Study of ADI-PEG 20 in Patients With Advanced Melanoma
NCT00518206Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
NCT01689870Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
NCT00006099Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
NCT00199849NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
NCT01838200Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
NCT00199875Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
NCT02431559Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
NCT00070070Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
NCT00199888Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
NCT02252211Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
NCT00293215Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
NCT06518837Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT00142415Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
NCT00616941Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00520533Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma
NCT00066729Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00199862Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
NCT00112229Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients